Stay updated on ARGX-113 in Myasthenia Gravis: Safety Trial
Sign up to get notified when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.

Latest updates to the ARGX-113 in Myasthenia Gravis: Safety Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page has removed a citation regarding the safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis, which is a significant study in the field.SummaryDifference0.4%
- Check24 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check38 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed trial descriptions and eligibility criteria for the ARGX-113 study, while a new revision number has been added.SummaryDifference14%
- Check46 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check89 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to ARGX-113 in Myasthenia Gravis: Safety Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-113 in Myasthenia Gravis: Safety Trial page.